Arcturus Therapeutics ARCT 深 沪
已收盘 02-06 16:00:00 美东时间
7.57
+0.550
+7.83%
华盛通- 最 高7.63
- 今 开7.24
- 成交量 57.03万股
- 最 低 7.01
- 昨 收 7.02
- 总市值 2.15亿
- 52周最高 24.17
- 市盈率 静 --
- 换手率 2.01%
- 52周最低 5.85
- 委 比 -75.94%
- 总股本 2841.43万
- 历史最高 129.71
- 量 比 1.14
- 振 幅 8.83%
- 历史最低 4.11
- 每 手 1
- 风险率 4.40%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 拼多多、小鹏获Freedom上调目标价；多家大行首予Wealthfront"超配"评级，目标价最高23美元
今日重点评级关注：HC Wainwright & Co.：维持MetaVia Inc."买入"评级，目标价从12美元升至40美元；Canaccord Genuity：维持GH Research"买入"评级，目标价从35美元升至39美元
01-07 17:25
Citigroup Maintains Neutral on Arcturus Therapeutics, Lowers Price Target to $7
Citigroup analyst Yigal Nochomovitz maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Neutral and lowers the price target from $9 to $7.
01-07 02:38
Arcturus Therapeutics Holdings Files For Mixed Shelf Of Up To $500M
Common StockPreferred StockDebt SecuritiesWarrantsRightsUnits__________________________From time to time, we may offer and sell up to an aggregate of $500,000,000 of any combination of the securities described in this
2025-12-31 05:04
Cathie Wood's weekly recap: heads turn to AI, biotech; sells communication names
Cathie Wood’s ARK Invest executed a busy week of portfolio adjustments across its ETFs, with several high-conviction additions and notable sell-offs. Major Weekly Buys Ark Invest strengthened convicti...
2025-12-08 18:22
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
2025-11-14 10:43
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
2025-11-12 11:43
HC Wainwright & Co. Maintains Neutral on Arcturus Therapeutics, Lowers Price Target to $9
HC Wainwright & Co. analyst Andrew S. Fein maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Neutral and lowers the price target from $12 to $9.
2025-11-12 00:27
Arcturus Therapeutics Q3 EPS $(0.49) Beats $(0.90) Estimate, Sales $17.151M Miss $21.196M Estimate
Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.90) by 45.49 percent. This is a 88.46 percent decrease over losses of $(0.26) per share
2025-11-11 05:01
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
2025-11-10 19:12
美股大行评级 | 升至45美元！英特尔获多家机构上调目标价；大摩上调拖拉机供应公司(TSCO)评级至"标配"，目标价升至60美元
今日重点评级关注：HC Wainwright & Co.：维持Alto Neuroscience"买入"评级，目标价从10美元升至50美元；RBC Capital：维持Precision Drilling"跑赢大市"评级，目标价从110美元升至117美元
2025-10-27 09:45
